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Abstract
Introduction Snail, a family of transcriptional repressors
implicated in cell movement, has been correlated with tumour
invasion. The Plasminogen Activation (PA) system, including
urokinase plasminogen activator (uPA), its receptor and its
inhibitor, plasminogen activator inhibitor type 1(PAI-1), also
plays a key role in cancer invasion and metastasis, either through
proteolytic degradation or by non-proteolytic modulation of cell
adhesion and migration. Thus, Snail and the PA system are both
over-expressed in cancer and influence this process. In this
study we aimed to determine if the activity of SNAI1 (a member
of the Snail family) is correlated with expression of the PA
system components and how this correlation can influence
tumoural cell migration.
Methods We compared the invasive breast cancer cell-line
MDA-MB-231 expressing SNAI1 (MDA-mock) with its derived
clone expressing a dominant-negative form of SNAI1 (SNAI1-
DN). Expression of PA system mRNAs was analysed by cDNA
microarrays and real-time quantitative RT-PCR. Wound healing
assays were used to determine cell migration. PAI-1 distribution
was assessed by immunostaining.
Results We demonstrated by both cDNA microarrays and real-
time quantitative RT-PCR that the functional blockade of SNAI1
induces a significant decrease of PAI-1 and uPA transcripts.
After performing an in vitro wound-healing assay, we observed
that SNAI1-DN cells migrate more slowly than MDA-mock cells
and in a more collective manner. The blockade of SNAI1 activity
resulted in the redistribution of PAI-1 in SNAI1-DN cells
decorating large lamellipodia, which are commonly found
structures in these cells.
Conclusions In the absence of functional SNAI1, the
expression of PAI-1 transcripts is decreased, although the
protein is redistributed at the leading edge of migrating cells in
a manner comparable with that seen in normal epithelial cells.
Introduction
Epithelial-mesenchymal transition (EMT) is a process whereby
epithelial cell layers lose polarity and cell-cell contacts and
undergo a dramatic remodelling of the cytoskeleton. EMT is
characterised by a loss of intercellular adhesion, down-regula-
tion of epithelial markers, up-regulation of mesenchymal mark-Page 1 of 12
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migration [1,2]. Many of the molecular changes occurring dur-
ing developmental EMT are also characteristics of most
aggressive metastatic cancer cells [2-5].
Important in EMT is the Snail family of transcriptional repres-
sors whose members including SNAI1, also known as snail,
and SNAI2, also known as slug [6]. One of the major effects
of Snail family molecules is the induction of a mesenchymal
and invasive phenotype [7]. This process includes alterations
in the expression of a wide number of proteins involved in cell-
to-cell and cell-to-extracellular matrix interactions, as well as
cytoskeletal reorganisation and migration [7,8]. When over-
expressed in epithelial Madin Darby Canin Kidney (MDCK)
cells, SNAI1 induces a full EMT leading to the acquisition of a
motile, invasive phenotype [9,10]. In agreement with this role,
SNAIl has also been found to down-regulate the expression of
epithelial genes, including E-cadherin [11-14] and to induce
the expression of mesenchymal genes [15,16]. Conversely,
Olmeda and colleagues demonstrated that SNAI1 silencing
by stable RNA interference in MDCK-SNAI1 cells induced a
complete mesenchymal to epithelial transition (MET), associ-
ated with the up-regulation of E-cadherin and down-regulation
of mesenchymal markers [17].
In several tumours, including breast cancers, SNAI1 has been
correlated with invasive growth potential, partly because of its
ability to directly repress transcription of genes whose prod-
ucts are involved in cell-cell adhesion [11,15,18,19]. Several
studies have shown that SNAI1 is found in the invasive regions
of tumours [15,20,21]. Moreover, Blanco and colleagues [18]
have reported that SNAI1 expression is correlated with both
histological grade and lymph node extension in breast can-
cers.
It has also been established that plasminogen activator inhibi-
tor-1 (PAI-1), urokinase plasminogen activator (uPA) and uPA
receptor (uPAR), members of the plasminogen activation sys-
tem (PA system), play a key role in cancer invasion and metas-
tasis [22,23]. PAI-1 is over-expressed in the immediate vicinity
of tumours [24], and preferentially localised to the stromal area
[25]. In addition to catalysing the degradation of the extracel-
lular matrix (ECM) and modulating cell adhesion [26], the PA
system enhances both cell proliferation [27] and migration
[28-34]. Consistent with their role in cancer dissemination,
high levels of uPA, PAI-1 and uPAR correlate with adverse
patient outcome [35-37]. In particular, the prognostic value of
PAI-1 has recently been validated in breast cancer patients
[38]. PAI-1 may represent a key molecule in the rapid attach-
ment/detachment events required for cell migration, by its abil-
ity to both decrease its affinity for vitronectin in the ECM and
to increase its affinity for endocytic receptors such as the lipo-
protein receptor-related protein (LRP) in response to PA bind-
ing [33,39-43]. It has also been demonstrated that PAI-1 can
induce cell behaviour changes, such as proliferation of cancer
cells, indirectly through cell signalling pathways [44]. Thus,
PAI-1 can modulate cell adhesion and migration via direct
interactions with integrins, LRP, uPA-uPAR and with the ECM
[43,45,46], or through indirect classical signalling pathways.
Both SNAI1 and PA system components play a major role in
tumour migration and have been localised to the tumour lead-
ing edge [15,20,21,24,25]. Moreover, three recently pub-
lished studies directly or indirectly underline a link between the
over-expression of SNAI1 and the PA system. In the first [47],
a dichotomous role for the transcription factor AFT3 in cancer
is demonstrated. This factor up-regulates the expression of
PAI-1, uPA and SNAI1 in breast cancer cells. The second arti-
cle [48] shows, using colon cancer cells, that the induction of
SNAI1 expression represses diverse genes, including uPAR,
involved in epithelial differentiation, metabolism and signalling.
In the third paper, it has been shown that over-expression of
SNAI1 and SNAI2 in canine kidney epithelial cells leads to
over-expression of PAI-1 [9].
In the present study, a 'reverse' analysis was used in breast
cancer cells where the activity of SNAI1 had been abolished,
with the aim of examining a possible link between SNAI1 and
PAI-1 during EMT, a process occurring during tumour pro-
gression.
Our data show that functional blockade of SNAI1 (SNAI1-
dominant negative (DN)) leads to a partial re-expression of E-
cadherin, and induces differential expression of EMT-related
genes. This is confirmed by RT-PCR of PA system genes,
where PAI-1 and uPA are decreased. In SNAI1-DN cells, cell
migration is quantitatively decreased, and this is associated
with morphological changes with SNAI1-DN cells displaying a
more collective behaviour compared with MDA-mock cells
that tend to migrate individually. PAI-1 is differently distributed
in SNAI1-DN cells, with numerous lamellipodia decorated with
anti-PAI-1 antibodies, compared with MDA-mock cells that
demonstrate a more homogeneous distribution of PAI-1.
Materials and methods
Chemicals and reagents for cell culture
Leibovitz's L-15 Medium with GlutaMAX, penicillin-streptomy-
cin, trypsin-EDTA and PBS were all purchased from GIBCO®
Invitrogen Cell Culture (Paisley, UK). FCS was purchased
from Bio Media (Quebec, Canada). BSA was purchased from
Sigma (Saint Louis, USA).
Cells and cell culture
Three established cell lines were used in this study: MDA-MB-
231, an invasive breast cancer cell line, and two derived
clones obtained after stable transfection with either an empty
pcDNA3 plasmid (clone MDA-mock) or with a dominant neg-
ative (DN) construct of SNAI1, pcDNA3-DN-SNAI1 lacking
the N-terminal SNAG domain (clone SNAI1-DN) [10].Page 2 of 12
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promoter that induces high-level constitutive expression in a
variety of mammalian cell lines, notably in epithelial and
endothelial cells. The high quantity of SNAI1-DN protein pro-
duced by the pcDNA3 vector should therefore be sufficient to
overcome the short half-life of this protein.
Cells were grown in Leibovitz's L-15 Medium with GlutaMAX
supplemented with 10% FCS, 100 U/mL penicillin and 100 U/
mL streptomycin. Cultures were selected with 400 μg/mL
G418 to generate stable cell lines and maintained in exponen-
tial growth in a humidified atmosphere at 37°C without carbon
dioxide. Cells were fed every third day and only used at pas-
sage four to seven for the experiments. All experiments were
performed three times on each of the three cell lines cultivated
in usual conditions (three days in Leibovitz's L-15 Medium
completed with FCS).
Cell staining and immunocytochemistry
4', 6-diamidino-2-phenylindole (DAPI), dihydrochloride Alexa
Fluor 568 phalloïdin and Alexa Fluor 488 secondary antibod-
ies were used in this study (Invitrogen – Molecular Probe –
Fischer Bioblock Scientific, Illkirch, France).
For F-actin and DAPI staining, culture medium was aspirated
and cells washed three times with PBS+/+ and fixed by incuba-
tion with prepared formaldehyde 3.7% in PBS-/- (pH 7.4) for
10 minutes at room temperature. Cells were again washed
three times in PBS-/- and permeabilised for three minutes with
Triton 0.1%. After three washings, specific sites were satu-
rated with 1% BSA in PBS-/- for 20 minutes, and incubated
with 5 U/mL Alexa Fluor 568 phalloïdin for 30 minutes. Cells
were washed three times with PBS-/- and incubated with 300
nM DAPI for four minutes. After PBS-/- washing, fixed stained
cells were stored in PBS-/- at 4°C before immunostaining.
For immunostaining, cells were incubated with primary anti-
bodies: antibodies anti-PAI-1 (1:50) (polyclonal rabbit anti-
PAI-1 H-135 primary antibody, Santa Cruz Biotechnology;
Santa Cruz, CA, USA); antibody anti E-cadherin (1:200) (mon-
oclonal mouse anti E-cadherin; BD Biosciences, le Pont de
Claix, France), during two hours.
Primary antibodies were revealed (one hour incubation) with
Alexa Fluor 488 secondary antibodies (anti-rabbit IgG 1:200;
anti-mouse IgG 1:200). Stained cells were mounted under
coverslips in Mowiol buffer.
Samples were examined using a 40×/1.30 Plan-Neofluar oil
immersion objective lens on an Apo Tome Axiovert 200 (Zeiss,
Le Pecq, France). All images were analysed using AxioVision
4.0 (Zeiss, Le Pecq, France) and figures were assembled
using Adobe Photoshop 6.0 (Adobe System, Paris, France).
Microarray analysis
Total RNA from the different cell lines was extracted using Tri-
zol reagent (Life Technologies Inc., Gaithersburg, MD, USA)
as indicated by the manufacturer. To synthesise the double-
stranded cDNA, 3 μg of total RNA using T7-(dThd) 24 oligo
primers by the Superscript Choice System (Life Technologies
Inc., Gaithersburg, MD, USA) was used. In vitro transcription
was conducted with Megascript T7 (Ambion, Austin, TX,
USA). Amplified RNA was obtained and purified using Trizol
reagent, and 3 μg of amplified RNA was used to generate flu-
orescence antisense RNAs by transcriptional synthesis using
the SuperScript enzyme protocol (Life Technologies Inc.,
Gaithersburg, MD). All of the samples were labelled with either
Cy5-dUTP or Cy3-dUTP fluorochromes (Amersham, Uppsala,
Sweden). Hybridisation was performed into the 'CNIO Onco-
chip' cDNA microarray v 1.1c (CNIO Genomic Unit, Madrid,
Spain) as previously described [49]. The microarray platform
contains 9726 clones corresponding to 6386 different genes,
which includes 2489 clones that have been printed in dupli-
cate to assess reproducibility. Duplicate samples from the
SNAI1-DN transfectant were labelled with dUTP-Cy5 and
hybridised against the dUTP-Cy3-labelled MDA-mock con-
trols. Two hybridisations were performed. Slides were
washed, dried and then scanned in a Scanarray 5000 XL
scanner (GSI Lumonics, Kanata, Ontario, Canada) to obtain
10 μm resolution images, which were then quantified using the
GenePix Pro 5.0 program (Axon Instruments Inc., Union City,
CA). Data from the fluorescence intensity measurements of
each array experiment were processed using GenePix Pro 5.0
and Microsoft Excel programs, as described before [49]. For
statistical analysis, we selected genes with expressions that
differed by a factor of at least two-fold with respect to the
MDA-mock control cells.
RNA extraction and real-time quantitative RT-PCR
Total RNA was isolated from cell cultures as previously
described by Chomczynski and colleagues [50]. RNA quantity
and RNA purity were performed by spectrophotometry using
GeneQuant II DNA/RNA calculator (Pharmacia Biotech, Pis-
cataway, N.J, USA). RNA integrity was checked by electro-
phoresis performed on agarose gel. Samples were then
treated by DNase I (Invitrogen, Cergy Pontoise, France) in
order to remove contaminating genomic DNA. An amount of 1
μg of total RNA was reverse-transcribed using random hexam-
ers as primers and Superscript II reverse transcriptase (Invitro-
gen, Cergy Pontoise, France). Real-time quantitative RT-PCR
of the obtained cDNA was performed in triplicate on an ABI
Prism 7000 Sequence Detection System (Applied Biosys-
tems, Courtaboeuf, France).
In these conditions, the expression of mRNAs encoding for
PAI-1, uPA and uPAR was quantified using assay-on-demand
TaqMan MGB probes Hs00170182_m1 (uPA),
Hs00182181_m1 (uPAR), Hs00167155_m1 (PAI-1) prede-
veloped from Applied Biosystems (Courtaboeuf, France),Page 3 of 12
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quencher. We used 18S RNA as control to normalise gene
expression using assay-on-demand TaqMan MGB probe
Hs99999901_s1 (Applied Biosystems, Courtaboeuf, France).
Then, 5 ng cDNA was used as template for real-time PCR. The
thermal cycler parameters for the real-time PCR were two min-
utes at 50°C (incubation with AmpErase UNG), 10 minutes at
95°C (activation of Taq polymerase) followed by 40 cycles
with 15 seconds at 95°C and one minute at 60°C. All of these
steps (with associated products) were performed according
to the recommendations of the manufacturer.
The relative expression level of the genes was calculated by
measuring the threshold cycle (CT) (using version 1.1 software
from the ABI Prism 7000 Sequence Detection System) and
use of the comparative CT method as described by the pro-
vider (ABI Prism user bulletin #2). Levels of transcripts in the
different clones (MDA-mock, SNAI1-DN) were determined in
reference to those obtained for the parental MDA-MB-231 cell
line cultured in FCS (the latter being standardised to one).
Semi-quantitative RT-PCR analysis for detection of E-cadherin
and glyceraldehyde-3-phosphate dehydrogenase was also
performed, using appropriate primers as previously described
[51].
In vitro wound healing assay
In vitro wound-healing assay was performed as previously
described [15,52]. MDA-mock and SNAI1-DN cells were
seeded on tissue culture dishes. Cell monolayers were then
gently scratched with a pipette tip across the entire diameter
of the dish and extensively rinsed with medium to remove all
cellular debris. The area of denuded surface (500 to 700 μm
in width) was quantified immediately after wounding and again
three and five hours later. The extent of wound closure was
determined by calculating the ratio between the surface area
of the wound for each time point and the surface of the initial
wound. These data were then expressed as the percentage of
wound closure relative to the control conditions for each
experiment. The dish was placed under an Axiovert 200
inverted microscope (Zeiss, Le Pecq, France) and images
were obtained using a high-resolution microscopic camera
Axiocam MRm vers.3 FireWire (D) camera (Zeiss, Le Pecq,
France) connected to the microscope. Phase-contrast pic-
tures were analysed by AxioVision 4.0 software (Zeiss, Le
Pecq, France).
Statistical analysis
The data were analysed using a Student's t-test (GraphPad
Software Inc., San Diego, CA, USA), and p < 0.05 were con-
sidered to indicate significant differences.
Results and discussion
SNAI1 functional blockade and E-cadherin expression
In order to study the possible link between SNAI1 and the PA
system during tumour progression, the MDA-MB-231 cell line,
an invasive breast cancer cell line was used to generate stable
cell lines transfected with a dominant-negative construct of
SNAI1 lacking the N-terminal transactivation domain SNAG
[8]. This dominant-negative version is able to interact with the
same target sequences as endogeneous SNAI1, thus block-
ing SNAI1 function when it is over-expressed.
As shown in Figure 1a, the MDA control cell line transfected
with the control vector (mock) maintained the same non-epi-
thelial phenotype as parental MDA-MB-231 cells, and showed
few cell-cell contacts. Performing semi-quantitative RT-PCR
analysis with E-cadherin, we demonstrated that SNAI1 func-
tional blockade lead to the re-expression of E-cadherin mRNA
in MDA-MB-231 cells (Figure 1c). However, E-cadherin immu-
nostaining is not clearly found at cell-cell contacts (Figure 1b),
as would be expected in an epithelial phenotype, and western
blot did not show any 120 kD protein (data not shown). This
absence of E-cadherin protein in SNAI1-DN cells suggests
that E-cadherin degradation still occurs when we abolish the
effect of SNAIl in our cancer cells. Indeed, in addition to tran-
scriptional control, considered to be the major mechanism reg-
ulating E-cadherin expression, recent data also suggest that
post-translational mechanisms, such as ubiquitination, endo-
cytosis and lysosomal degradation of E-cadherin, occur during
EMT, and are important for both embryological development
and tumour progression [53,54].
These observations are consistent with recently published
work using MDA-MB-231 cell lines stably transfected by short
hairpin RNA directed against SNAI1 to knock-down SNAI
expression [55]. These studies showed an increase of E-cad-
herin mRNA level but no E-cadherin protein expression and a
decrease in the expression of the mesenchymal markers,
fibronectin and vimentin, suggesting that SNAI1 silencing
induces a partial reversion of EMT in MDA-MB-231. Moreover,
Janda and colleagues indicate that the early stages of EMT
involve post-translational down-regulation of E-cadherin,
whereas loss of E-cadherin via transcriptional repression is a
late event in EMT [56]. In the reversion of EMT (i.e. MET), we
can hypothesise that a reverse situation would be observed:
expression of E-cadherin first at transcriptional level and then
at translational and post-translational levels.
To further highlight the relation between SNAI1 and the PA
system in EMT occuring during tumour progression, we used
cDNA microarrays to compare MDA-mock and SNAI1-DN cell
by differential gene expression.Page 4 of 12
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Of 6386 genes compared (microarray accession number
[GSE:10395] deposited in the Gene Expression Omnibus), a
total of 99 genes were found to be differentially expressed in
response to SNAI1 functional blockade [see Additional data
file 1]. As shown in Table 1, nine of the 99 target genes differ-
entially expressed in SNAI1-DN clone are specifically impli-
cated in EMT and in matrix remodelling, these include several
members of the PA system. Of particular note, the expression
of PAI-1 is decreased 7.2-fold in the SNAI1-DN clone (Table
1), compared with the MDA-mock clone.
These data are similar to those obtained [9] that demonstrated
that PAI-1 was the most affected gene after over-expression of
SNAI1. These data are also in agreement with several studies
showing that PA system components are involved in tumour
evolution [22,23] including tumoural transitions EMT and mes-
enchymal to amoeboid transition (MAT)) [57-61]. Therefore,
we focused on PA system genes and confirmed the microarray
results by quantitative real-time RT-PCR. Both levels of PAI-1
and uPA transcripts were strongly decreased in SNAI1-DN
cells compared with MDA-mock cells, although uPAR tran-
scripts remained unchanged (Figure 2).
These results from more precise and sensitive methods, con-
firmed the microarray data and showed that the expression of
PA system component transcripts, especially PAI-1 and uPA,
are dependent on SNAI1 functionality.
This relation between SNAI1 and the PA system is consistent
with the observations of Kuphal and colleagues [61] and Hou
and colleagues [62]. Kuphal and colleagues, using melanoma
cells, pointed out that the loss of E-cadherin leads to the up-
regulation of NFkB activity, and that after re-expression of E-
cadherin, NFkB activity was down-regulated [62]; while Hou
and colleagues demonstrated that NFkB activity independ-
ently induces the expression of PAI-1 [63]. We therefore
hypothesise that in the SNAI1-DN cells the functional defi-
ciency of SNAI1 leads to the re-expression of E-cadherin (Fig-
ure 1), which in turn down-regulates NFkB leading to the
decreased expression of PAI-1 mRNA.
Figure 1
Immunofluorescence analysis of E-cadherin (green) in MDA-mock and SNAI1-DN cellsunofluorescence analysis of E-cadherin (green) in MDA-mock and SNAI1-DN cells. Nuclei are visualised by 4', 6-diamidino-2-phenylin-
dole (DAPI) stain. (a) The MDA-mock control cell line transfected with a control vector (mock) presents no cell-cell contact, and the immunostaining 
of E-cadherin is very low and diffused. (b1) SNAI1-DN cells have acquired an epithelial like phenotype with E-cadherin stronger expression (b2) 
sometimes organised specifically at cell-cell contacts. (c) Semi-quantitative RT-PCR analysis of E-cadherin mRNA in MDA-mock and SNAI1-DN 
cells. GADPH mRNA levels were detected as a control of cDNA inputs. SNAI1-DN expression in MDA-MB-231 cells lead to the re-expression of E-
cadherin mRNA.Page 5 of 12
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through binding to E-boxes [8]. It is possible that functional
blockade of SNAI1 could have lead to an increase in PAI-1
expression rather than a decrease (Figure 2). However, in this
context, it is worth noting that Allen and colleagues suggested
that the E-box motif could function as a 'platform' for recruit-
ment of either positive and negative regulators of PAI-1
expression [64]. This implies that if the E-box is indeed the
pathway of SNAI1 influence, then its effect on PAI-1 transcrip-
tion cannot be easily anticipated. And this effect depends "on
the stimulus and/or the growth state" [64]. Moreover, Munshi
and colleagues showed that de novo E-cadherin mediates
adhesive contacts and leads to a decrease of the global PAI-
1 levels [65]. Whereas in the opposite situation – blockade of
E-cadherin-dependant cell-cell adhesion – a stimulation of
uPA expression was observed [66,67]. Consistent with these
latter studies, our data show a decrease of uPA transcript in
SNAI1-DN cells.
As numerous papers have already described, mechanisms of
cancer migration are dependant on uPA, and as PAI-1 tran-
scripts were the most affected by the changes in SNAI1
expression (over-expression or functional blockade), we
focused on the link between SNAI1 and PAI 1. Moreover, two
indirect arguments suggest a potential link between SNAI1
and PAI-1. Firstly, there is a strong correlation between SNAI1
expression and metastatic process [18,19,68-70], whereas,
SNAI1 repression decreases invasive behaviour [17,55]. Sec-
ondly, PAI-1 expression is correlated with adverse patient out-
come and metastatic disease [35,38], and is down-regulated
in our study after SNAI1 functional blockade.
Thus we suggest that either through E-cadherin expression
and NFkB regulation or through binding to the E-box motif,
SNAI1 is able to influence PAI-1 expression. This highlights
the pivotal role of SNAI1 in cancer cell migration, influencing
PAI-1, a key factor in metastatic cell escape. Therefore, we
focused our attention on this possible link between SNAI1 and
Table 1
Epithelial to mesenchymal transition (EMT) related genes modified in a clone expressing a dominant-negative form of SNAI1 
(SNAI1-DN) in comparison with MDA-mock control cells
GenBank number SNAI1-DN Description
EMT related (n = 9)
[Genbank:AA447737] -2.12 CALD1, caldesmon 1
[Genbank:AA284668] -2.45 PLAU, plasminogen activator, urokinase
[Genbank:AA136707] -2.12 PLOD2, procollagen-lysine, 2-oxoglutarate 5-dioxygenase (lysine hydroxylase) 2
[Genbank:N75719] -7.22 SERPINE1, serine (or cysteine) proteinase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), 
member 1
[Genbank:H96738] 2.29 CDH11, cadherin 11, type 2, OB-cadherin (osteoblast)
[Genbank:H15267] 2.48 CHL1, cell adhesion molecule with homology to L1CAM (close homologue of L1)
[Genbank:AA598794] 3.87 CTGF, connective tissue growth factor
[Genbank:W51794] 3.49 MMP3, matrix metalloproteinase 3 (stromelysin 1, progelatinase)
[Genbank:AA479202] 2.58 TIMP3, tissue inhibitor of metalloproteinase 3 (Sorsby fundus dystrophy, pseudo-inflammatory)
Nine of the 99 target genes differentially expressed in SNAI1-DN clone are implicated in the EMT process and matrix remodelling, including some 
members of the plasminogen activation system. Particularly, the expression of PAI-1 is decreased by 7.2-fold in SNAI1-DN clones. - = down-
regulation; + = up-regulation.
Figure 2
Expression of the Plasminogen Activation system (PA) system compo-nents mRNAs (Plasminogen Activator Inhibitor type-1 (PAI-1), uroki-ase Plasminog n Activat r (uP ), uroki ase Plasminogen Activator R c ptor (uPAR)) in SNAI1-DN versus MDA-mock cellression of the Plasmi ogen Activat on system ( ) syste  
components mRNAs (Plasminogen Activator Inhibitor type-1 (PAI-
1), urokinase Plasminogen Activator (uPA), urokinase Plasmino-
gen Activator Receptor (uPAR)) in SNAI1-DN versus MDA-mock 
cells. Steady state levels of the PA system component mRNAs were 
evaluated by real-time quantitative RT-PCR analysis of total RNA of 
SNAI1-DN and MDA-mock cells cultured as described. These levels 
are determined in reference to those obtained for the original MDA-MB-
231 cell line which were standardised to one. Mean values (standard 
error of the mean) of four independent cultures are shown.* p < 0.05.Page 6 of 12
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cells.
Quantitatively and qualitatively, the migration of SNAI1-
DN cells is modified
We performed an in vitro wound-healing assay to assess the
consequences of SNAI1 blockade. The migration of MDA-
mock and SNAI1-DN cells differs at three and five hours after
wounding with SNAI1-DN cells migrating almost twice as
slowly as MDA-mock cells (Figure 3a, b). These results are
consistent with the prognostic value of SNAI1 in tumoural dis-
ease and metastatic potential [8,71,72].
The cell populations of the two cell lines migrate differently in
terms of velocity (Figure 3). F-actin staining of the cells border-
ing the injury site also show morphological modifications of the
cell migration (Figure 4a). We observed that although parental
cells migrate primarily individually (i.e. as little groups of cells
or as individuals), SNAI1 blockade resulted in a more collec-
Figure 3
Quantitative changes in SNAI1-DN cell migrationitative changes in SNAI1-DN cell migration. The migratory 
behaviour of MDA-mock and SNAI1-DN cells is analysed in an in vitro 
wound healing assay. Monolayer cell cultures of MDA-mock and 
SNAI1-DN cells are gently scratched with a pipette tip to produce a 
wound. (a) Photographs of the cultures are taken immediately after the 
incision, and after three and five hours in culture. (b) The extent of 
wound closure is determined after three and five hours incubation. The 
comparison of MDA-mock and SNAI1-DN migration shows that SNAI1-
DN cells migrate significantly more slowly than MDA-mock cells five 
hours after wounding. Mean values (standard error of the mean) of four 
independent assays are shown.* p < 0.05.
Figure 4
Qualitative changes in SNAI1-DN cell migrationit tive changes in SNAI1-DN cell migration. In a wound healing 
assay, cells are fixed one, three and five hours after wounding. Together 
with the individual versus collective migration, morphological character-
istics reinforce the epithelial to mesenchymal transition (EMT) status of 
MDA-mock and inverse transition for SNAI1-DN cells. (a) Actin immu-
nostaining show that the MDA-mock cells move as individuals or as 
small groups of cells. The remaining population is not organised as a 
coherent group but rather as a juxtaposition of individuals. This is 
attested to by the presence of small groups of cells or individuals 
(white arrows) distinct from the leading edge (white line). In contrast, 
SNAI1-DN cells, moved as a coherent group, with a unique leading 
edge and large lamellipodia underlined by actin staining (see also figure 
5). (b) This picture (at four times lower magnification) generalises the 
individual versus collective behaviour of the MDA-mock and SNAI1-DN 
cells at the wound scale.Page 7 of 12
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appears not to be organised as a coherent group but rather as
a collection of individuals. This is demonstrated by the
absence of a unique leading edge, shown by actin cytoskele-
ton staining. In contrast, the SNAI1-DN cells, appeared to
move as a coherent group, with a unique leading edge (Figure
4a). This is even more apparent at the lower magnification (Fig-
ure 4b).
In addition to examining morphology of the mock and SNAI1-
DN cell lines, in wound healing assays, we noticed, as other
groups have [73], that individual migration is associated with
low E-cadherin expression while collective migration is associ-
ated with re-expression of E-cadherin.
During wound healing, SNAI1-DN cells display a 
homogeneous leading edge with lamellipodia
We characterised the morphology of the two cell lines,
because it is now well known that EMT can lead to the modifi-
cation of cell morphology and individual migration. In collective
migration, cellular groups migrate via a sequence of adhesion/
traction at the leading edge implicating actin-mediated ruffling,
invadopodia, integrin-mediated adhesion and recruitment of
surface proteases [57].
In the present study, higher magnification and F-actin staining
of the cells bordering the injury site (Figure 4a) show differ-
ences in the cell morphology of SNAI1-DN cells and MDA-
mock cells. SNAI1-DN cells moved as a coherent group with
a unique leading edge and numerous large lamellipodia under-
lined by actin staining and this migration was associated with
a homogeneous direction towards the wound (Figure 4a). In
contrast, in MDA-mock cells no lamellipodia and no similar
directionality could be observed.
PAI-1 distribution is modified in SNAI1-DN cells
PAI-1 immunostaining is rarely colocalised with F-actin struc-
tures in MDA-mock cells. In these cells, PAI-1 is preferentially
localised in the perinuclear region (Figure 5, MDA-mock). In
contrast, in SNAI1-DN cells not only is the nuclear area deco-
rated with PAI-1 antibodies, but so is the cell membrane and
particularly the lamellipodia (Figure 5, SNAI1-DN). It is inter-
esting to observe that in this cellular structure, PAI-1 and actin
are co-localised (Figure 5, SNAI1-DN, 'merged'). It has previ-
ously been observed that PAI-1 is produced after injury by
cells immediately adjacent to the wounding edge [74,75].
Providence and colleagues [75] demonstrated that in vitro
wounding resulted in the identification of a 'leading edge'
cohort (i.e. cells immediately adjacent to the wound border)
becoming polarised with extended membrane ruffles and
lamellipodia along the cellular 'face' juxtaposed to the
denuded zone. These leading-edge cells were particularly
immunoreactive with PAI-1 antibodies. Nevertheless, none of
these studies demonstrate a PAI-1 distribution in lamellipodia
associated with actin.
Taken together, the collective behaviour of cell migration, the
numerous large lamellipodia at the leading edge and the co-
localisation of actin with PAI-1 in lamellipodia, suggest that
SNAI1 functional blockade redirected the cancer cells toward
an epithelial-like cell behaviour. This behaviour is character-
ised by a lower expression of PAI-1 and altered distribution of
PAI-1 protein in the cell, especially during wound healing. Like-
wise, the increased expression of E-cadherin mRNA suggests
a partial recovery of epithelial properties in SNAI-DN cells. This
morphological epithelial behaviour could represent an early
step of the EMT reversion. Several studies have identified cells
displaying both epithelial and mesenchymal traits. These
'metastable' cells present both residual E-cadherin and collec-
tive migration, membrane extension [76].
Finally, as pointed out by Providence and colleagues [77], the
changes of PAI-1 expression and/or distribution to the cellular
under surface that we previously described may be of impor-
tance, because PAI-1 would then come in close contact to
focal contact sites [78]. These sites include integrin/vitronec-
tin–dependent contacts that may be modified by the level of
PAI-1 competing with integrins binding to vitronectin
[33,41,43,79-81]. Thus PAI-1 may induce variations of cell
attachment or detachment, especially in lamellipodia [43,82].
Figure 5
Modified distribution of Plasminogen Activator Inhibitor type-1 (PAI-1) in SNAI1-DN cellsi d distribution of Plasminogen Activator Inhibitor type-1 
(PAI-1) in SNAI1-DN cells. PAI-1 immunostaining is rarely co-localied 
with F-actin structures in MDA-mock cells. In these cells, PAI-1 is pref-
erentially localised in the perinuclear region. In contrast in SNAI1-DN-
cells, PAI-1 immunostaining is strongly localised in the numerous lamel-
lipodia and is more diffuse in the cytoplasm.Page 8 of 12
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tions with plasminogen activators and the endocytic receptor
LRP can control sequences of attachment/detachment in non-
tumour cells [45,46]. This is consistent with our data with
tumour cells presented here and suggests that in a similar way
PAI-1 could promote cancer metastasis rather than inhibiting
this process as predicted from studies of uPA. This could be
of particular importance as cell matrix detachment is provoked
by EMT inducers. The increase or decrease of PAI-1 expres-
sion is probably only one side of the story.
Focusing on the molecular and functional links between migra-
tion, E-cadherin, SNAI1 and PAI-1 we observed that elements
inducing SNAI1 transcription, such as transforming growth
factor beta, lead to the over-expression of PAI-1 and a
decrease in E-cadherin with the subsequent situation being
favourable to cell migration. In our study, the functional block-
ade of SNAI1 leads to reduced migration and redistribution of
PAI 1 stressing the tight inter-connections between cells and
their microenvironment.
In this regard, it may be important to highlight the differences
between soluble PAI-1 playing the unique role of uPA inhibitor
(i.e. decreasing proteolysis) and matrix bound PAI-1, which is
mainly a matricellular protein (linking the cell membrane to the
matrix) involved in cell adhesion/de-adhesion and migration
[30,45,46].
Our study suggests that SNAI1 regulates PAI-1 expression,
which is used as a matrix-bound regulator of cell migration
and/or as a soluble inhibitor of proteolysis, according to
SNAI1 function. Thus, SNAI1 [6] and PAI-1 [28-31,33,34]
may influence cancer cell migration but, depending on SNAI1
status, this could imply proteolysis-dependent migration, col-
lective or individual behaviour, and their consequences.
A better knowledge of the molecular requirements for EMT in
human cancer will lead to a better understanding of tumour
progression and to define more effective strategies for future
therapeutic interventions.
Conclusion
Both the transcription factor SNAI1 and the PA system influ-
ence cancer cell migration and are over-expressed in cancers.
In this study we aimed to determine whether SNAI1 activity is
correlated with expression of PA system components, and
how this correlation can influence tumoural cell migration.
Therefore, we compared the invasive breast cancer cell line
MDA-MB-231 expressing Snail (MDA-mock) with its derived
clone expressing a dominant-negative form of SNAI1 (SNAI1-
DN).
We demonstrated by both cDNA microarrays and real-time
quantitative RT-PCR that SNAI1-DN clone presents a signifi-
cant decrease of PAI-1 and uPA mRNA compared with MDA-
mock. With an in vitro wound healing assay, we observed that
SNAI1-DN cells migrate more slowly than MDA-mock cells
and in a more collective pathway. The blockade of SNAI1
activity resulted in the redistribution of PAI-1 in SNAI1-DN
cells decorating large lamellipodia.
Taken together these results suggest that SNAI1 functional
blockade is leading to partial re-expression of E-cadherin (i.e.
at the level of transcription), to a decrease in PAI-1 and to a
more collective migration, while the parental cells expressing
SNAI1 have less E-cadherin, more PAI 1, and migrate individ-
ually. We suggest that the present study establishes a relation
between SNAI1 function, PAI-1 distribution and EMT status.
Therefore, we believe that our results could lead to a better
understanding of the permissive conditions for metastatic
escape of cancer cells.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
EF-G and MM contributed equally to this study. EF-G and CC-
B performed RT-PCR, immunofluorescence analysis and
migration assays. CC-B performed the statistical analysis. HP,
AC, GM-B and JP participated in the construction of Snail-DN
clone and performed microarray assays. MM with AC-M car-
ried out the immunofluorescence analysis, migration assays
and conducted imaging studies. BV was involved in cell cul-
tures and in RT-PCR. EF-G, CC-B and MM participated in the
wound healing assays. GBM and DL were involved in design-
ing all experiments and writing the manuscript. All authors read
and approved the final manuscript.
Additional files
The following Additional files are available online:
Additional data file 1
Supplementary table
A table that lists the human genes up-regulated or down-
regulated in a clone expressing a dominant-negative form 
of SNAI1 (SNAI1-DN) compared with MDA-mock 
control cells. Negative sign (-) means down-regulation 
and positive sign (+) means up-regulation. Genes are 
organised by molecular function. A total of 99 genes 
were found to be differentially expressed, by at least a 
two-fold factor, in response to SNAI1 functional 
blockade.
See http://www.biomedcentral.com/content/
supplementary/bcr2203-S1.docPage 9 of 12
(page number not for citation purposes)
Breast Cancer Research    Vol 10 No 6    Fabre-Guillevin et al.Acknowledgements
This work was supported by the CNRS ACI Program "Complexité du 
vivant" (grant # 050009DR11) and by the Evry Genopole grant "Aide à 
l'acquisition d'équipement semi-lourd" 2007 and 2008.
References
1. Huber MA, Kraut N, Beug H: Molecular requirements for epithe-
lial-mesenchymal transition during tumor progression.  Curr
Opin Cell Biol 2005, 17:548-558.
2. Thiery JP, Sleeman JP: Complex networks orchestrate epithe-
lial-mesenchymal transitions.  Nat Rev Mol Cell Biol 2006,
7:131-142.
3. Bates RC, Bellovin DI, Brown C, Maynard E, Wu B, Kawakatsu H,
Sheppard D, Oettgen P, Mercurio AM: Transcriptional activation
of integrin beta6 during the epithelial-mesenchymal transition
defines a novel prognostic indicator of aggressive colon carci-
noma.  J Clin Invest 2005, 115:339-347.
4. Fuchs IB, Lichtenegger W, Buehler H, Henrich W, Stein H, Kleine-
Tebbe A, Schaller G: The prognostic significance of epithelial-
mesenchymal transition in breast cancer.  Anticancer Res
2002, 22:3415-3419.
5. Kang Y, Massague J: Epithelial-mesenchymal transitions: twist
in development and metastasis.  Cell 2004, 118:277-279.
6. Barrallo-Gimeno A, Nieto MA: The Snail genes as inducers of
cell movement and survival: implications in development and
cancer.  Development 2005, 132:3151-3161.
7. Peinado H, Olmeda D, Cano A: Snail, Zeb and bHLH factors in
tumour progression: an alliance against the epithelial pheno-
type?  Nat Rev Cancer 2007, 7:415-428.
8. Nieto MA: The snail superfamily of zinc-finger transcription
factors.  Nat Rev Mol Cell Biol 2002, 3:155-166.
9. Moreno-Bueno G, Cubillo E, Sarrio D, Peinado H, Rodriguez-
Pinilla SM, Villa S, Bolos V, Jorda M, Fabra A, Portillo F, Palacios J,
Cano A: Genetic profiling of epithelial cells expressing E-cad-
herin repressors reveals a distinct role for Snail, Slug, and E47
factors in epithelial-mesenchymal transition.  Cancer Res
2006, 66:9543-9556.
10. Peinado H, Ballestar E, Esteller M, Cano A: Snail mediates E-
cadherin repression by the recruitment of the Sin3A/histone
deacetylase 1 (HDAC1)/HDAC2 complex.  Mol Cell Biol 2004,
24:306-319.
11. Batlle E, Sancho E, Franci C, Dominguez D, Monfar M, Baulida J,
Garcia De Herreros A: The transcription factor snail is a repres-
sor of E-cadherin gene expression in epithelial tumour cells.
Nat Cell Biol 2000, 2:84-89.
12. Guaita S, Puig I, Franci C, Garrido M, Dominguez D, Batlle E, San-
cho E, Dedhar S, De Herreros AG, Baulida J: Snail induction of
epithelial to mesenchymal transition in tumor cells is accom-
panied by MUC1 repression and ZEB1 expression.  J Biol
Chem 2002, 277:39209-39216.
13. Ikenouchi J, Matsuda M, Furuse M, Tsukita S: Regulation of tight
junctions during the epithelium-mesenchyme transition: direct
repression of the gene expression of claudins/occludin by
Snail.  J Cell Sci 2003, 116:1959-1967.
14. Martinez-Estrada OM, Culleres A, Soriano FX, Peinado H, Bolos V,
Martinez FO, Reina M, Cano A, Fabre M, Vilaro S: The transcrip-
tion factors Slug and Snail act as repressors of Claudin-1
expression in epithelial cells.  Biochem J 2006, 394:449-457.
15. Cano A, Perez-Moreno MA, Rodrigo I, Locascio A, Blanco MJ, del
Barrio MG, Portillo F, Nieto MA: The transcription factor snail
controls epithelial-mesenchymal transitions by repressing E-
cadherin expression.  Nat Cell Biol 2000, 2:76-83.
16. Jorda M, Olmeda D, Vinyals A, Valero E, Cubillo E, Llorens A, Cano
A, Fabra A: Upregulation of MMP-9 in MDCK epithelial cell line
in response to expression of the Snail transcription factor.  J
Cell Sci 2005, 118:3371-3385.
17. Olmeda D, Jorda M, Peinado H, Fabra A, Cano A: Snail silencing
effectively suppresses tumour growth and invasiveness.
Oncogene 2007, 26:1862-1874.
18. Blanco MJ, Moreno-Bueno G, Sarrio D, Locascio A, Cano A, Pala-
cios J, Nieto MA: Correlation of Snail expression with histolog-
ical grade and lymph node status in breast carcinomas.
Oncogene 2002, 21:3241-3246.
19. Cheng CW, Wu PE, Yu JC, Huang CS, Yue CT, Wu CW, Shen
CY: Mechanisms of inactivation of E-cadherin in breast carci-
noma: modification of the two-hit hypothesis of tumor sup-
pressor gene.  Oncogene 2001, 20:3814-3823.
20. Franci C, Takkunen M, Dave N, Alameda F, Gomez S, Rodriguez R,
Escriva M, Montserrat-Sentis B, Baro T, Garrido M, Bonilla F, Vir-
tanen I, Garcia de Herreros A: Expression of Snail protein in
tumor-stroma interface.  Oncogene 2006, 25:5134-5144.
21. Sugimachi K, Tanaka S, Kameyama T, Taguchi K, Aishima S, Shi-
mada M, Sugimachi K, Tsuneyoshi M: Transcriptional repressor
snail and progression of human hepatocellular carcinoma.
Clin Cancer Res 2003, 9:2657-2664.
22. Binder BR, Mihaly J: The plasminogen activator inhibitor "para-
dox" in cancer.  Immunol Lett 2008, 118:116-124.
23. Duffy MJ, McGowan PM, Gallagher WM: Cancer invasion and
metastasis: changing views.  J Pathol 2008, 214:283-293.
24. Wilkins-Port CE, Higgins CE, Freytag J, Higgins SP, Carlson JA,
Higgins PJ: PAI-1 is a Critical Upstream Regulator of the TGF-
beta1/EGF-Induced Invasive Phenotype in Mutant p53 Human
Cutaneous Squamous Cell Carcinoma.  J Biomed Biotechnol
2007, 2007:85208.
25. Pedersen TX, Pennington CJ, Almholt K, Christensen IJ, Nielsen
BS, Edwards DR, Romer J, Dano K, Johnsen M: Extracellular pro-
tease mRNAs are predominantly expressed in the stromal
areas of microdissected mouse breast carcinomas.  Carcino-
genesis 2005, 26:1233-1240.
26. Chorostowska-Wynimko J, Skrzypczak-Jankun E, Jankun J: Plas-
minogen activator inhibitor type-1: its structure, biological
activity and role in tumorigenesis (Review).  Int J Mol Med
2004, 13:759-766.
27. Jo M, Thomas KS, Marozkina N, Amin TJ, Silva CM, Parsons SJ,
Gonias SL: Dynamic assembly of the urokinase-type plas-
minogen activator signaling receptor complex determines the
mitogenic activity of urokinase-type plasminogen activator.  J
Biol Chem 2005, 280:17449-17457.
28. Bonavaud S, Charriere-Bertrand C, Rey C, Leibovitch MP, Peder-
sen N, Frisdal E, Planus E, Blasi F, Gherardi R, Barlovatz-Meimon
G: Evidence of a non-conventional role for the urokinase tri-
partite complex (uPAR/uPA/PAI-1) in myogenic cell fusion.  J
Cell Sci 1997, 110(Pt 9):1083-1089.
29. Chazaud B, Bonavaud S, Plonquet A, Pouchelet M, Gherardi RK,
Barlovatz-Meimon G: Involvement of the [uPAR:uPA:PAI-1:LRP]
complex in human myogenic cell motility.  Exp Cell Res 2000,
258:237-244.
30. Chazaud B, Ricoux R, Christov C, Plonquet A, Gherardi RK, Barlo-
vatz-Meimon G: Promigratory effect of plasminogen activator
inhibitor-1 on invasive breast cancer cell populations.  Am J
Pathol 2002, 160:237-246.
31. Planus E, Barlovatz-Meimon G, Rogers RA, Bonavaud S, Ingber
DE, Wang N: Binding of urokinase to plasminogen activator
inhibitor type-1 mediates cell adhesion and spreading.  J Cell
Sci 1997, 110(Pt 9):1091-1098.
32. Samarakoon R, Higgins CE, Higgins SP, Kutz SM, Higgins PJ:
Plasminogen activator inhibitor type-1 gene expression and
induced migration in TGF-beta1-stimulated smooth muscle
cells is pp60(c-src)/MEK-dependent.  J Cell Physiol 2005,
204:236-246.
33. Waltz DA, Natkin LR, Fujita RM, Wei Y, Chapman HA: Plasmin
and plasminogen activator inhibitor type 1 promote cellular
motility by regulating the interaction between the urokinase
receptor and vitronectin.  J Clin Invest 1997, 100:58-67.
34. Wang Z, Sosne G, Kurpakus-Wheater M: Plasminogen activator
inhibitor-1 (PAI-1) stimulates human corneal epithelial cell
adhesion and migration in vitro.  Exp Eye Res 2005, 80:1-8.
35. Harbeck N, Kates RE, Schmitt M, Gauger K, Kiechle M, Janicke F,
Thomassen C, Look MP, Foekens JA: Urokinase-type plasmino-
gen activator and its inhibitor type 1 predict disease outcome
and therapy response in primary breast cancer.  Clin Breast
Cancer 2004, 5:348-352.
36. Sakakibara T, Hibi K, Kodera Y, Ito K, Akiyama S, Nakao A: Plas-
minogen activator inhibitor-1 as a potential marker for the
malignancy of esophageal squamous cell carcinoma.  Clin
Cancer Res 2004, 10:1375-1378.
37. Seetoo DQ, Crowe PJ, Russell PJ, Yang JL: Quantitative expres-
sion of protein markers of plasminogen activation system in
prognosis of colorectal cancer.  J Surg Oncol 2003,
82:184-193.
38. Biermann JC, Holzscheiter L, Kotzsch M, Luther T, Kiechle-Bahat
M, Sweep FC, Span PN, Schmitt M, Magdolen V: QuantitativePage 10 of 12
(page number not for citation purposes)
Available online http://breast-cancer-research.com/content/10/6/R100RT-PCR assays for the determination of urokinase-type plas-
minogen activator and plasminogen activator inhibitor type 1
mRNA in primary tumor tissue of breast cancer patients: com-
parison to antigen quantification by ELISA.  Int J Mol Med 2008,
21:251-259.
39. Lauffenburger DA, Horwitz AF: Cell migration: a physically inte-
grated molecular process.  Cell 1996, 84:359-369.
40. Deng G, Curriden SA, Wang S, Rosenberg S, Loskutoff DJ: Is
plasminogen activator inhibitor-1 the molecular switch that
governs urokinase receptor-mediated cell adhesion and
release?  J Cell Biol 1996, 134:1563-1571.
41. Stefansson S, Lawrence DA: The serpin PAI-1 inhibits cell
migration by blocking integrin alpha V beta 3 binding to vit-
ronectin.  Nature 1996, 383:441-443.
42. Stefansson S, Muhammad S, Cheng XF, Battey FD, Strickland DK,
Lawrence DA: Plasminogen activator inhibitor-1 contains a
cryptic high affinity binding site for the low density lipoprotein
receptor-related protein.  J Biol Chem 1998, 273:6358-6366.
43. Stefansson S, Su EJ, Ishigami S, Cale JM, Gao Y, Gorlatova N,
Lawrence DA: The contributions of integrin affinity and
integrin-cytoskeletal engagement in endothelial and smooth
muscle cell adhesion to vitronectin.  J Biol Chem 2007,
282:15679-15689.
44. Croucher DR, Saunders DN, Stillfried GE, Ranson M: A structural
basis for differential cell signalling by PAI-1 and PAI-2 in
breast cancer cells.  Biochem J 2007, 408:203-210.
45. Cao C, Lawrence DA, Li Y, Von Arnim CA, Herz J, Su EJ, Makarova
A, Hyman BT, Strickland DK, Zhang L: Endocytic receptor LRP
together with tPA and PAI-1 coordinates Mac-1-dependent
macrophage migration.  Embo J 2006, 25:1860-1870.
46. Stefansson S, Lawrence DA: Old dogs and new tricks: pro-
teases, inhibitors, and cell migration.  Sci STKE 2003,
2003:pe24.
47. Yin X, Dewille JW, Hai T: A potential dichotomous role of ATF3,
an adaptive-response gene, in cancer development.  Onco-
gene 2008, 27:2118-2127.
48. De Craene B, Gilbert B, Stove C, Bruyneel E, van Roy F, Berx G:
The transcription factor snail induces tumor cell invasion
through modulation of the epithelial cell differentiation pro-
gram.  Cancer Res 2005, 65:6237-6244.
49. Moreno-Bueno G, Sanchez-Estevez C, Cassia R, Rodriguez-
Perales S, Diaz-Uriarte R, Dominguez O, Hardisson D, Andujar M,
Prat J, Matias-Guiu X, Cigudosa JC, Palacios J: Differential gene
expression profile in endometrioid and nonendometrioid
endometrial carcinoma: STK15 is frequently overexpressed
and amplified in nonendometrioid carcinomas.  Cancer Res
2003, 63:5697-5702.
50. Chomczynski P, Sacchi N: Single-step method of RNA isolation
by acid guanidinium thiocyanate-phenol-chloroform extrac-
tion.  Anal Biochem 1987, 162:156-159.
51. Perez-Moreno MA, Locascio A, Rodrigo I, Dhondt G, Portillo F,
Nieto MA, Cano A: A new role for E12/E47 in the repression of
E-cadherin expression and epithelial-mesenchymal transi-
tions.  J Biol Chem 2001, 276:27424-27431.
52. Bolos V, Peinado H, Perez-Moreno MA, Fraga MF, Esteller M,
Cano A: The transcription factor Slug represses E-cadherin
expression and induces epithelial to mesenchymal transi-
tions: a comparison with Snail and E47 repressors.  J Cell Sci
2003, 116:499-511.
53. Palacios F, Tushir JS, Fujita Y, D'Souza-Schorey C: Lysosomal
targeting of E-cadherin: a unique mechanism for the down-
regulation of cell-cell adhesion during epithelial to mesenchy-
mal transitions.  Mol Cell Biol 2005, 25:389-402.
54. Yang JY, Zong CS, Xia W, Wei Y, Ali-Seyed M, Li Z, Broglio K,
Berry DA, Hung MC: MDM2 promotes cell motility and invasive-
ness by regulating E-cadherin degradation.  Mol Cell Biol
2006, 26:7269-7282.
55. Olmeda D, Moreno-Bueno G, Flores JM, Fabra A, Portillo F, Cano
A: SNAI1 is required for tumor growth and lymph node metas-
tasis of human breast carcinoma MDA-MB-231 cells.  Cancer
Res 2007, 67:11721-11731.
56. Janda E, Nevolo M, Lehmann K, Downward J, Beug H, Grieco M:
Raf plus TGFbeta-dependent EMT is initiated by endocytosis
and lysosomal degradation of E-cadherin.  Oncogene 2006,
25:7117-7130.
57. Friedl P: Prespecification and plasticity: shifting mechanisms
of cell migration.  Curr Opin Cell Biol 2004, 16:14-23.
58. Malo M, Charriere-Bertrand C, Chettaoui C, Fabre-Guillevin E,
Maquerlot F, Lackmy A, Vallee B, Delaplace F, Barlovatz-Meimon
G: [The PAI-1 swing: microenvironment and cancer cell migra-
tion].  C R Biol 2006, 329:919-927.
59. Santibanez JF: JNK mediates TGF-beta1-induced epithelial
mesenchymal transdifferentiation of mouse transformed
keratinocytes.  FEBS Lett 2006, 580:5385-5391.
60. Wilkins-Port CE, Higgins PJ: Regulation of extracellular matrix
remodeling following transforming growth factor-beta1/epi-
dermal growth factor-stimulated epithelial-mesenchymal
transition in human premalignant keratinocytes.  Cells Tissues
Organs 2007, 185:116-122.
61. Yoshino I, Kometani T, Shoji F, Osoegawa A, Ohba T, Kouso H,
Takenaka T, Yohena T, Maehara Y: Induction of epithelial-mes-
enchymal transition-related genes by benzo[a]pyrene in lung
cancer cells.  Cancer 2007, 110:369-374.
62. Kuphal S, Poser I, Jobin C, Hellerbrand C, Bosserhoff AK: Loss of
E-cadherin leads to upregulation of NFkappaB activity in
malignant melanoma.  Oncogene 2004, 23:8509-8519.
63. Hou B, Eren M, Painter CA, Covington JW, Dixon JD, Schoenhard
JA, Vaughan DE: Tumor necrosis factor alpha activates the
human plasminogen activator inhibitor-1 gene through a distal
nuclear factor kappaB site.  J Biol Chem 2004,
279:18127-18136.
64. Allen RR, Qi L, Higgins PJ: Upstream stimulatory factor regu-
lates E box-dependent PAI-1 transcription in human epidermal
keratinocytes.  J Cell Physiol 2005, 203:156-165.
65. Munshi HG, Ghosh S, Mukhopadhyay S, Wu YI, Sen R, Green KJ,
Stack MS: Proteinase suppression by E-cadherin-mediated
cell-cell attachment in premalignant oral keratinocytes.  J Biol
Chem 2002, 277:38159-38167.
66. Frixen UH, Nagamine Y: Stimulation of urokinase-type plas-
minogen activator expression by blockage of E-cadherin-
dependent cell-cell adhesion.  Cancer Res 1993,
53:3618-3623.
67. Kleiner S, Faisal A, Nagamine Y: Induction of uPA gene expres-
sion by the blockage of E-cadherin via Src- and Shc-depend-
ent Erk signaling.  Febs J 2007, 274:227-240.
68. Come C, Magnino F, Bibeau F, De Santa Barbara P, Becker KF,
Theillet C, Savagner P: Snail and slug play distinct roles during
breast carcinoma progression.  Clin Cancer Res 2006,
12:5395-5402.
69. Martin TA, Goyal A, Watkins G, Jiang WG: Expression of the
transcription factors snail, slug, and twist and their clinical sig-
nificance in human breast cancer.  Ann Surg Oncol 2005,
12:488-496.
70. Zhou BP, Deng J, Xia W, Xu J, Li YM, Gunduz M, Hung MC: Dual
regulation of Snail by GSK-3beta-mediated phosphorylation in
control of epithelial-mesenchymal transition.  Nat Cell Biol
2004, 6:931-940.
71. Elloul S, Elstrand MB, Nesland JM, Trope CG, Kvalheim G, Gold-
berg I, Reich R, Davidson B: Snail, Slug, and Smad-interacting
protein 1 as novel parameters of disease aggressiveness in
metastatic ovarian and breast carcinoma.  Cancer 2005,
103:1631-1643.
72. Moody SE, Perez D, Pan TC, Sarkisian CJ, Portocarrero CP,
Sterner CJ, Notorfrancesco KL, Cardiff RD, Chodosh LA: The
transcriptional repressor Snail promotes mammary tumor
recurrence.  Cancer Cell 2005, 8:197-209.
73. Martin-Villar E, Megias D, Castel S, Yurrita MM, Vilaro S, Quinta-
nilla M: Podoplanin binds ERM proteins to activate RhoA and
promote epithelial-mesenchymal transition.  J Cell Sci 2006,
119:4541-4553.
74. Maquerlot F, Galiacy S, Malo M, Guignabert C, Lawrence DA,
d'Ortho MP, Barlovatz-Meimon G: Dual role for plasminogen
activator inhibitor type 1 as soluble and as matricellular regu-
lator of epithelial alveolar cell wound healing.  Am J Pathol
2006, 169:1624-1632.
75. Providence KM, White LA, Tang J, Gonclaves J, Staiano-Coico L,
Higgins PJ: Epithelial monolayer wounding stimulates binding
of USF-1 to an E-box motif in the plasminogen activator inhib-
itor type 1 gene.  J Cell Sci 2002, 115:3767-3777.
76. Lee JM, Dedhar S, Kalluri R, Thompson EW: The epithelial-mes-
enchymal transition: new insights in signaling, development,
and disease.  J Cell Biol 2006, 172:973-981.
77. Providence KM, Kutz SM, Staiano-Coico L, Higgins PJ: PAI-1
gene expression is regionally induced in wounded epithelialPage 11 of 12
(page number not for citation purposes)
Breast Cancer Research    Vol 10 No 6    Fabre-Guillevin et al.cell monolayers and required for injury repair.  J Cell Physiol
2000, 182:269-280.
78. Kutz SM, Hordines J, McKeown-Longo PJ, Higgins PJ: TGF-
beta1-induced PAI-1 gene expression requires MEK activity
and cell-to-substrate adhesion.  J Cell Sci 2001,
114:3905-3914.
79. Czekay RP, Loskutoff DJ: Unexpected role of plasminogen acti-
vator inhibitor 1 in cell adhesion and detachment.  Exp Biol
Med (Maywood) 2004, 229:1090-1096.
80. Kjoller L, Kanse SM, Kirkegaard T, Rodenburg KW, Ronne E,
Goodman SL, Preissner KT, Ossowski L, Andreasen PA: Plas-
minogen activator inhibitor-1 represses integrin- and vitronec-
tin-mediated cell migration independently of its function as an
inhibitor of plasminogen activation.  Exp Cell Res 1997,
232:420-429.
81. Takahashi T, Suzuki K, Ihara H, Mogami H, Kazui T, Urano T: Plas-
minogen activator inhibitor type 1 promotes fibrosarcoma cell
migration by modifying cellular attachment to vitronectin via
alpha(v)beta(5) integrin.  Semin Thromb Hemost 2005,
31:356-363.
82. Schmidt CE, Horwitz AF, Lauffenburger DA, Sheetz MP: Integrin-
cytoskeletal interactions in migrating fibroblasts are dynamic,
asymmetric, and regulated.  J Cell Biol 1993, 123:977-991.Page 12 of 12
(page number not for citation purposes)
